Guardant Health, Inc. $GH Shares Acquired by Inceptionr LLC

Inceptionr LLC increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 89.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,762 shares of the company’s stock after acquiring an additional 6,029 shares during the quarter. Inceptionr LLC’s holdings in Guardant Health were worth $1,179,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new stake in Guardant Health in the 4th quarter valued at about $27,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Guardant Health in the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health in the fourth quarter valued at approximately $35,000. Parallel Advisors LLC increased its position in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares during the last quarter. Finally, EFG International AG acquired a new position in Guardant Health during the fourth quarter worth approximately $41,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on GH shares. Wolfe Research assumed coverage on Guardant Health in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 target price on the stock. UBS Group set a $150.00 price target on Guardant Health in a research note on Wednesday, June 24th. Evercore reaffirmed an “outperform” rating and issued a $200.00 price objective on shares of Guardant Health in a research note on Monday, July 6th. JPMorgan Chase & Co. boosted their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Morgan Stanley increased their target price on shares of Guardant Health from $130.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $160.04.

Guardant Health Stock Down 0.4%

Shares of NASDAQ:GH opened at $150.20 on Friday. The company has a market capitalization of $19.92 billion, a price-to-earnings ratio of -44.31 and a beta of 1.59. The company has a 50 day moving average of $138.36 and a two-hundred day moving average of $111.70. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $174.08.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 10,000 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the transaction, the director directly owned 11,183 shares of the company’s stock, valued at $1,420,017.34. This represents a 47.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the sale, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. This represents a 10.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 708,565 shares of company stock worth $90,556,597 over the last three months. Insiders own 5.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.